Phibro Q1 Sales Rise 6% to $386.8M, FY2027 Guidance Held
PAHC sits 39% above its 52-week low of $28.25.
Summary
Phibro opened fiscal 2027 with net sales of $386.8 million, up 6% year over year, and adjusted diluted EPS of $0.79 versus $0.73 a year ago. Net income rose 11% to $29.5 million. Management said the quarter beat its own plan, led by Mineral Nutrition (sales up 17% on higher zinc oxide, copper and trace mineral prices) and Performance Products (up 16%), while core Animal Health grew 3% with adjusted EBITDA slightly below last year at $73.9 million. The company kept FY2027 guidance unchanged at $1.55-$1.60 billion in net sales and $258-$268 million in adjusted EBITDA, and the outlook still assumes no additional virginiamycin sales in Brazil — CEO Dani Bendheim flagged that a Brazilian regulatory approval for therapeutic claims would be pure upside. Gross leverage sits at 2.9x with $739.6 million of total debt. The earnings call is November 5 at 9:00 AM ET.
At the time of this announcement, PAHC was trading at $39.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $28.25 to $60.08. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.